FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says
You may also be interested in...
Safety Reporting For OTCs Should Allow Targeted Risk Management – CHPA
FDA ought to consider targeted questionnaires for specific types of suspected adverse drug reactions (SADRs) rather than an "active query" approach when dealing with OTC products, CHPA says
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands